Sandra Richman

Biogen (United States) — United States

Medicine · Health Sciences

14h-index3.0kcitations28works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Polyomavirus and related diseases(15), Full-Duplex Wireless Communications(9), Multiple Sclerosis Research Studies(7), Plant Virus Research Studies(5), Antenna Design and Analysis(3)

Publications28 total

Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies
The Lancet Neurology·2017· 310 cited
Infants and children with SMA treated with nusinersen in clinical trials: experience of risk for respiratory or other events with repeat anesthesia/sedation for intrathecal administration
Neuromuscular Disorders·2017
Infants and children with SMA treated with nusinersen in clinical trials: an integrated safety analysis
Neuromuscular Disorders·2017· 2 cited
Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study
BMC Neurology·2016· 128 citedOpen Access
Medication utilization among pediatric-onset multiple sclerosis patients in the United States
Journal of the Neurological Sciences·2015Open Access
Anti-JC Virus (JCV) Antibody Index Differentiates Risk of Progressive Multifocal Leukoencephalopathy (PML) in Natalizumab-Treated Multiple Sclerosis (MS) Patients with No Prior Immunosuppressant (IS) Use: An Updated Analysis (P4.031)
Neurology·2015· 13 cited
Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy
Journal of NeuroVirology·2015· 95 citedOpen Access
Outcome and survival of asymptomatic <scp>PML</scp> in natalizumab‐treated <scp>MS</scp> patients
Annals of Clinical and Translational Neurology·2014· 124 citedOpen Access
Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab‐associated progressive multifocal leukoencephalopathy
Annals of Neurology·2014· 427 citedOpen Access
Anti‐<scp>JC</scp> virus (<scp>JCV</scp>) antibody prevalence in the <scp>JCV</scp> Epidemiology in <scp>MS</scp> (<scp>JEMS</scp>) trial
European Journal of Neurology·2013· 98 cited
Longitudinal Stability of Anti-JC Virus Antibody Status in Multiple Sclerosis Patients: Results of STRATIFY-1 (S30.001)
Neurology·2013
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Survey of Anesthesiology·2012· 15 cited
JCV Epidemiology in MS (JEMS): prevalence of anti-JC virus antibodies in multiple sclerosis patients
2012· 1 cited
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
New England Journal of Medicine·2012· 1.2k citedOpen Access
Final Results from the AVONEX(R) (Intramuscular Interferon Beta-1a) Pregnancy Exposure Registry (P06.191)
Neurology·2012· 8 cited
Anti-JCV Antibody Prevalence in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Natalizumab: Baseline Results of STRATIFY-2 (S41.002)
Neurology·2012· 20 cited
Classification of Natalizumab Cases with Progressive Multifocal Leukoencephalopathy (P07.058)
Neurology·2012· 4 cited
Updated Incidence of Progressive Multifocal Leukoencephalopathy in Natalizumab-Treated Multiple Sclerosis Patients Stratified by Established Risk Factors (S41.001)
Neurology·2012
Preoperative Chemoradiotherapy for Esophageal Cancer
2012
Anti‐John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY‐1
Annals of Neurology·2011· 141 cited
page 1 of 2Next →

Frequent Co-authors

Meena Subramanyam(13), Gary Bloomgren(12), Tatiana Plavina(11), Carmen Bozic(11), Sophia Lee(6), Alfred Sandrock(5), Barry Ticho(4), Madé Wenten(4), Sarah Gheuens(4), Christophe Hotermans(3), Susan Goelz(3), Amy Natarajan(3), James Scanlon(3), Tuan Dong‐Si(3), Nancy Richert(3), Xiao Hu(3), Larisa Miller(3), Stacy Hitchman(3), Gabrielle Glick(3), Shifang Liu(3)